Autism - Drug Pipeline Analysis and Market Forecasts to 2016

Autism - Drug Pipeline Analysis and Market Forecasts to 2016

Summary

GlobalData, the industry analysis specialist’s new report, “Autism - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global autism market, a key segment within the pharmaceutical and healthcare industry. This pharma report identifies the key trends shaping and driving the global autism market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global autism sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:

• Annualized global autism market revenues data from 2001 to 2009, forecast forward for seven years to 2016.
• Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.
• Pipeline analysis data, providing a split across different phases by mechanism of action being developed and emerging trends. Key classes of mechanism of action include 5-HT2A and D2 receptors antagonists, serotonin inhibitors, glutamate antagonists, antioxidants, cholinergic agents and immune response down regulators.
• Analysis of the current and future market competition in the global autism market. Key market players covered are Repligen Corporation, BioMarin Pharmaceuticals, and Neuropharm Group Plc.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for future market associated with autism.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global autism market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global autism market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global autism market landscape? – Identify, understand and capitalize.

1 Table of contents

1.1 List of Tables

1.2 List of Figures

2 Autism Market: Market Characterization

2.1 Overview

2.2 Autism Therapeutics Market Size

2.3 Autism Market Forecast and CAGR

2.4 Drivers and Barriers for the Autism Therapeutics Market

2.4.1 Drivers for the Autism Therapeutics Market

2.4.2 Barriers for the Autism Therapeutics Market

2.5 Opportunity and Unmet Need

2.6 Key Takeaway

3 Autism Market: Competitive Assessment

3.1 Overview

3.2 Strategic Competitor Assessment

3.3 Product Profile for the Major Marketed Products in the Autism Therapeutics Market

3.3.1 Risperdal

3.3.2 Abilify

3.4 Key Takeaway

4 Autism Market: Pipeline Assessment

4.1 Overview

4.2 Strategic Pipeline Assessment

4.2.1 Technology Trends Analytic Framework

4.3 Autism Therapeutics - Promising Drugs under Clinical Development

4.4 Molecule Profile for Promising Drugs under Clinical Development

4.4.1 Galantamine

4.4.2 Atomoxetine

4.4.3 Fluoxetine

4.5 Autism Market - Clinical Pipeline by Mechanism of Action

4.6 Autism Pipeline - Pipeline by Clinical Phases of Development

4.6.1 Autism Disorder Therapeutics - Phase III Clinical Pipeline

4.6.2 Autism Therapeutics - Phase II Clinical Pipeline

4.6.3 Autism Therapeutics - Phase I Clinical Pipeline

4.6.4 Autism Therapeutics - Discovery Pipeline

4.7 Key Takeaway

5 Autism Market: Implications for Future Market Competition

6 Autism Market: Future Players in the Autism Market

6.1 Introduction

6.2 Repligen Corporation

6.2.1 Overview

6.2.2 Major Products and Services

6.2.3 Autism Disease Portfolio

6.2.4 RG1068

6.3 BioMarin Corporation

6.3.1 Overview

6.3.2 Major Products and Services

6.3.3 Autism Disease Portfolio

6.3.4 Kuvan

6.4 Neuropharm Group PLC

6.4.1 Overview

6.4.2 Major Products and Services

6.4.3 Autism Disease Portfolio

6.4.4 Fluoxetine

7 Autism Market: Appendix

7.1 Definitions

7.2 Acronyms

7.3 Research Methodology

7.3.1 Coverage

7.3.2 Secondary Research

7.3.3 Forecasting

7.3.4 Primary Research

7.3.5 Expert Panel Validation

7.4 Contact Us

7.5 Disclaimer

7.6 Sources